MCM
NVCR icon

MAI Capital Management’s NovoCure NVCR Stock Holding History

MAI Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$818 Buy
75
+17
+29% +$212 ﹤0.01% 4248
2025
Q4 		$750 Buy
58
+16
+38% +$205 ﹤0.01% 3722
2025
Q3 		$543 Sell
42
-130
-76% -$1.74K ﹤0.01% 3606
2025
Q2 		$3.06K Buy
172
+130
+310% +$2.27K ﹤0.01% 3274
2025
Q1 		$749 Hold
42
– – ﹤0.01% 3183
2024
Q4 		$1.25K Buy
+42
New +$889 ﹤0.01% 3140

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

MAI Capital Management's NVCR Position: Q1 2026 in Review

MAI Capital Management increased its NovoCure (NVCR) stake by 29% in Q1 2026, buying an estimated $212 and bringing the position to 75 shares worth $818. The position accounts for ﹤0.01% of the portfolio, ranked #4248.

MAI Capital Management first reported a position in NVCR in Q4 2024 and has held it in 6 quarters since. The position peaked at $3.06K in Q2 2025. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • MAI Capital Management held 75 shares of NovoCure worth $818 as of Q1 2026.
  • MAI Capital Management bought 17 NovoCure shares in Q1 2026, an estimated $212.
  • NovoCure made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4248 holding.
  • MAI Capital Management first reported a position in NovoCure in Q4 2024 and has held it in 6 quarters since.
  • MAI Capital Management's NovoCure position peaked at $3.06K in Q2 2025.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.